Patents by Inventor Alan Engelman

Alan Engelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inhibition of retroviruses
    Patent number: 8927510
    Abstract: Described herein are methods and compositions for the inhibition of retroviral integration and replication. The methods and compositions inhibit the activity of one or more components of the SET complex or base excision repair enzymes and induce autointegration of retroviral double-stranded nucleic acid.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: January 6, 2015
    Assignees: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Nan Yan, Alan Engelman, Judy Lieberman
  • COMPOSITIONS AND METHODS FOR INHIBITION OF RETROVIRUSES
    Publication number: 20110142854
    Abstract: Described herein are methods and compositions for the inhibition of retroviral integration and replication. The methods and compositions inhibit the activity of one or more components of the SET complex or base excision repair enzymes and induce autointegration of retroviral double-stranded nucleic acid.
    Type: Application
    Filed: May 18, 2009
    Publication date: June 16, 2011
    Applicants: IMMUNE DISEASE INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nan Yan, Alan Engelman, Judy Lieberman
  • Ndr kinase modulators
    Publication number: 20070031822
    Abstract: Methods of identifying agents that modulate NDR kinases, including those that modulate NDR1 and NDR2 kinases and methods of using those agents to inhibit retroviral pathogenesis are among the methods described herein.
    Type: Application
    Filed: January 22, 2004
    Publication date: February 8, 2007
    Inventors: Eric Devroe, Alan Engelman, Pamela Silver
  • Episomally replicating lentiviral vectors
    Patent number: 6808923
    Abstract: The invention is directed to a lentiviral vector system that can be used for episomal replication of a desired gene. The vector system contains a first vector containing a lentiviral gag gene encoding a lentiviral gag protein, a second vector containing an env gene encoding a functional envelope protein, and a lentiviral pol gene encoding a lentiviral pol protein. The pol protein is at least integrase, but that the integrase has been modified so that it is not capable of integration. This pol gene can be on the first or second vectors or on a third vector. The lentiviral gag and pol and the envelope protein are not on a single vector, and these vectors do not contain nucleotides to effectively package lentiviral RNA. The system also contains another vector having a nucleic acid sequence encoding a target molecule operably linked to a component of an episomal replicon and a lentiviral packaging sequence.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: October 26, 2004
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan Engelman, Wolfgang Hofmann, Joseph G. Sodroski, Richard Lu
  • Episomally replicating lentiviral vectors
    Publication number: 20030013196
    Abstract: The invention is directed to a lentiviral vector system that can be used for episomal replication of a desired gene. The vector system contains a first vector containing a lentiviral gag gene encoding a lentiviral gag protein, a second vector containing an env gene encoding a functional envelope protein, and a lentiviral pol gene encoding a lentiviral pol protein. The pol protein is at least integrase, but that the integrase has been modified so that it is not capable of integration. This pol gene can be on the first or second vectors or on a third vector. The lentiviral gag and pol and the envelope protein are not on a single vector, and these vectors do not contain nucleotides to effectively package lentiviral RNA. The system also contains another vector having a nucleic acid sequence encoding a target molecule operably linked to a component of an episomal replicon and a lentiviral packaging sequence.
    Type: Application
    Filed: November 21, 2001
    Publication date: January 16, 2003
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan Engelman, Wolfgang Hofmann, Joseph Sodroski, Richard Lu